Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Biohaven Pharmaceutical

National Institute for Health and Care Excellence NICE logo

Pfizer faces NICE rejection for cancer drug Bosulif

Draft guidance says drug is not cost-effective in chronic myeloid leukaemia

- PMLiVE

FDA looks at new use for BMS/Pfizer’s Eliquis

Could provide a welcome new indication for the anticoagulant

- PMLiVE

Pfizer expands Xeljanz manufacturing capability in Ireland

Invests $130m in manufacturing in Dublin and Cork

- PMLiVE

Pfizer wins new European approval for Prevenar 13

Expands use of pneumococcal disease vaccine to cover people aged 18 to 49

UK launch for Pfizer’s long-acting contraceptive injection Sayana

Becomes first contraceptive of its kind to reach the UK market

Synexus South Africa research sites join Pfizer trial network

CRO's sites become the first in Africa to meet the pharma company's standards

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

Pfizer pulls late-stage trial of cancer drug in NHL

Inotuzumab ozogamicin fails to show survival benefit in phase III

- PMLiVE

Pfizer launches online home delivery service for Viagra

Partners with CVS/pharmacy on e-commerce initiative

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Pfizer cuts 2013 forecast after weak first quarter

Revenues down 9 per cent as key drugs face generic competition

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links